Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
(Values in U.S. thousands)
| 04-2026 | 04-2025 | 04-2024 | 04-2023 | 04-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 711 | 3,949 | 376 | 5,141 | 14,064 |
| TOTAL | $1,765 | $4,177 | $455 | $5,836 | $14,414 |
| Non-Current Assets | |||||
| PPE Net | 315 | 426 | 176 | 80 | 103 |
| TOTAL | $315 | $426 | $176 | $80 | $103 |
| Total Assets | $2,079 | $4,603 | $632 | $5,916 | $14,516 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,346 | 635 | 2,925 | 2,870 | 1,165 |
| TOTAL | $1,346 | $635 | $3,226 | $2,870 | $1,165 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,346 | $635 | $3,226 | $2,870 | $1,165 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 4,792 | 2,896 | 93 | 72 | 71 |
| Common Shares | 0 | 0 | 0 | 0 | 10 |
| Retained earnings | -67,308 | -58,535 | -54,020 | -44,073 | -29,195 |
| Other shareholders' equity | 0 | 0 | 0 | -14,883 | -14,883 |
| TOTAL | $733 | $3,968 | $-2,594 | $3,046 | $13,352 |
| Total Liabilities And Equity | $2,079 | $4,603 | $632 | $5,916 | $14,516 |